Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | UBE2M | P61081 | 2/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24317697 | 0.89 | KMT2A (0.56) | KMT2AMEN1RAB9AOPRM1SIGMAR1 | |
| SCHEMBL27009996 | 0.89 | OPRM1 (0.51) | OPRM1SIGMAR1CHRM2CHRM3 | |
| SCHEMBL27009997 | 0.83 | PGR (0.50) | KMT2AMEN1RAB9ARORC | |
| SCHEMBL24317700 | 0.82 | UBE2M (0.43) | UBE2MDCUN1D1 | |
| SCHEMBL21674344 | 0.81 | OPRM1 (0.60) | KMT2AMEN1RAB9AOPRM1SIGMAR1 | |
| SCHEMBL24316253 | 0.81 | ACHE (0.49) | OPRM1SIGMAR1 | |
| SCHEMBL24316247 | 0.78 | OPRM1 (0.47) | KMT2AMEN1RAB9AOPRM1SIGMAR1 | |
| SCHEMBL27009995 | 0.77 | MEN1 (0.47) | KMT2AMEN1OPRM1RORCUBE2M | |
| SCHEMBL24317704 | 0.77 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL13080536 | 0.76 | OPRM1 (0.54) | KMT2AMEN1RAB9AOPRM1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | KMT2A 1574/4885MEN1 2331/4885RAB9A 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.